RDHL - RedHill Biopharma Ltd.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2000 |
| Open | 2.1800 |
| Bid | 2.2300 x 900 |
| Ask | 2.2700 x 2200 |
| Day's Range | 2.1657 - 2.2898 |
| 52 Week Range | 2.0400 - 49.2000 |
| Volume | |
| Avg. Volume | 95,963 |
| Market Cap | 6.577M |
| Beta (5Y Monthly) | 2.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -48.6600 |
| Earnings Date | Jun 21, 2023 - Jun 26, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
Fair Value
Related Research
PR NewswireRedHill Provides R&D Update
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the termination of RHB-204's[1] U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to a very low accrual rate, and the shifting of the Company's resources to advance once-daily, oral RHB-107's[2] late-stage development for outpatient treatment of COVID-19. This decision is intended to enable the Company to better focus its resources on key pipeline cataly
- PR Newswire
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated May 9, 2023 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares ("MVPHS") set forth in the Nasdaq Rules for continued Nasdaq listing.
- PR Newswire
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced two distinct sets of new Talicia[3] data focused on generic non-bioequivalence and on dosing regimens. The first new dataset, published in the Journal Alimentary Pharmacology and Therapeutics (AP&T) showed that generically substituted regimens are non-bioequivalent to Talicia. The second set of data, presented at Digestive Disease Week (DDW), supports bioequivalence between Talici
- PR Newswire
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of two new EU and U.S. patents for RHB-102 (BEKINDA)1 and opaganib2, respectively, in the oncology setting.
- PR Newswire
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its fourth quarter and full year 2022 financial results and operational highlights.
Simply Wall St.Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet
To the annoyance of some shareholders, RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shares are down a considerable 41% in the...
- PR Newswire
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5450(a)(1), the Company was requir
- PR Newswire
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,500,000 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 A
- PR Newswire
RedHill Biopharma Announces $6 Million Registered Direct Offering
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,500,000 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, series A warrants to purchase up to an aggregate of 1,500,000 ADSs and series B warrants to purchase up to an aggregate of 1,500,000 ADSs at a purchase price
- Simply Wall St.
RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt
Key Insights The considerable ownership by individual investors in RedHill Biopharma indicates that they collectively...
- PR Newswire
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the availability of a warranty program for its Helicobacter pylori (H. pylori) eradication therapy, Talicia®[4], in which RedHill commits to reimburse patient out of pocket costs should Talicia not work. Talicia is the most prescribed branded agent by gastroenterologists[2] and this warranty commitment extends to all commercially insured and non-insured Talicia patients who comple
- PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Company's American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS representing ten (10) ordinary shares to a new ratio of one (1) ADS representing four hundred (400) ordinary shares. The anticipated first date of the ratio change is on or about March 23, 2023, and the Company's
- PR Newswire
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, with a single investor, for the issuance of convertible promissory note in the principal amount of up to $6 million, convertible into American Depositary Shares ("ADS") and warrants to purchase ADSs of the Company, pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended.
ACCESSWIRERedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
RedHill Biopharma Ltd. (Nasdaq:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has selected opaganib[1] for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome (ARS).
- PR Newswire
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has selected opaganib1 for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome (ARS). As part of this collaboration, contractors directed and
- ACCESSWIRE
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
RedHill Biopharma Ltd. (Nasdaq:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102 (Bekinda)[i] for oncology support (management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, also referred
- PR Newswire
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102 (Bekinda)[1] for oncology support (management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, also referred to as CINV and RINV) in adults and childr
- PR Newswire
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the positive outcome of a scheduled Type B meeting with the U.S. Food and Drug Administration (FDA) for the development of opaganib for Acute Radiation Syndrome (ARS) in which the FDA provided guidance on opaganib's developmental pathway to potential approval under the Animal Rule.
American City Business JournalsRaleigh pharma sheds debt in exchange for top-selling drug. Now what?
A Raleigh company is giving up its top revenue generating product in exchange for the cancelation of more than $100 million in debt. Now, it must find a viable path forward.
- PR Newswire
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the extinguishment of all RedHill's debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill's U.S. subsidiary RedHill Biopharma Inc. and HCR dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affili
- PR Newswire
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the granting of a patent covering RHB-204's1 oral fixed-dose combination, methods for treating pulmonary Mycobacterium avium Complex (MAC) disease, and kits comprising a supply of fixed-dose combination products for treating pulmonary MAC disease. Once issued, the patent is expected to pro
BenzingaRedHill Biopharma Shares Jump After Data Publication From COVID-19 Study
RedHill Biopharma Ltd (NASDAQ: RDHL) announced the publication of positive data from a Phase 2 study RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases. The study showed that RHB-107 met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and a 100% reduction
- PR Newswire
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 (upamostat)[2] in non-hospitalized symptomatic COVID-19 patients, in the peer-reviewed International Journal of Infectious Diseases[3]. The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the
American City Business Journals2022 Year in Review: Layoffs hit Triangle biotech, pharma companies
After record levels of funding poured into life sciences companies during the pandemic, economic conditions turned 2022 into a much more difficult year.
ACCESSWIREAegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL).